---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088581"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:29:24.036721+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q2 net loss $37.3M; FDA clinical hold on diabetes trials; topline readouts on track for Q4

## Summary
- Net loss $37.3M in Q2 vs $24.9M YoY; cash $113.7M, down from $177.2M end of 2023.
- FDA imposed full clinical hold on BMF-219 diabetes trials due to hepatotoxicity concerns.
- Topline data from Phase 2b (type 2, ~195 pts) and Phase 2a (type 1, ~20 pts) still expected Q4 2024.
- Third obesity program (oral GLP-1R agonist) to be announced Q3 2024.
- Two COVALENT-101 cohorts (CLL, DLBCL) discontinued due to insufficient enrollment.

## SEC filing metadata
- accession: 0000950170-24-088581
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017024088581/0000950170-24-088581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017024088581/bmea-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088581
- JSON: https://secwatch.observer/filing/0000950170-24-088581.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.